CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $66.06 Average PT from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has been given a consensus recommendation of “Moderate Buy” by the nineteen ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, six have issued a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $65.4706.

Several brokerages have recently issued reports on CRSP. Sanford C. Bernstein boosted their price target on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a report on Wednesday. Bank of America reduced their price target on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Wall Street Zen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Monday, April 20th. Finally, Citizens Jmp reduced their price objective on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th.

Insider Buying and Selling

In related news, insider Naimish Patel sold 3,150 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the sale, the insider owned 13,143 shares of the company’s stock, valued at $634,281.18. This represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 10,020 shares of the company’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares of the company’s stock, valued at $11,952,336.78. The trade was a 3.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 51,828 shares of company stock valued at $2,578,097 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of CRSP. GSK plc acquired a new stake in CRISPR Therapeutics in the fourth quarter worth about $168,890,000. Orbis Allan Gray Ltd raised its position in CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after acquiring an additional 1,201,600 shares in the last quarter. SR One Capital Management LP raised its position in CRISPR Therapeutics by 94.4% in the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock worth $132,132,000 after acquiring an additional 989,812 shares in the last quarter. State Street Corp raised its position in CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after acquiring an additional 859,334 shares in the last quarter. Finally, ARK Investment Management LLC raised its position in CRISPR Therapeutics by 7.5% in the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after acquiring an additional 735,084 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $48.41 on Tuesday. CRISPR Therapeutics has a 1 year low of $35.38 and a 1 year high of $78.48. The company has a market cap of $4.67 billion, a price-to-earnings ratio of -7.78 and a beta of 1.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97. The firm has a fifty day moving average of $51.49 and a 200-day moving average of $53.77.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The firm had revenue of $1.46 million for the quarter. As a group, equities analysts anticipate that CRISPR Therapeutics will post -5.08 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.